Mitotane (MTT) is the treatment of choice for adrenocortical carcinoma. Male hypogonadism is often diagnosed in male patients treated with this drug. This research aims to consider possible side effects induced by MTT in the testis and a hypothetical detrimental effect deriving from androgenic deficiency. Furthermore, considering the increased potentiality of treatment for adrenocortical carcinoma, we want to provide male patients of childbearing age, as in other oncological diseases, the opportunity to consider a sperm cryopreservation program.
Effect of Mitotane on Male Gonadal Function / Innocenti, Federica; Di Persio, Sara; Taggi, Marilena; Maggio, Roberta; Lardo, Pina; Toscano, Vincenzo; Canipari, Rita; Vicini, Elena; Stigliano, Antonio. - In: CANCERS. - ISSN 2072-6694. - 15:12(2023). [10.3390/cancers15123234]
Effect of Mitotane on Male Gonadal Function
Toscano, Vincenzo;Canipari, Rita;Vicini, Elena
;Stigliano, Antonio
2023
Abstract
Mitotane (MTT) is the treatment of choice for adrenocortical carcinoma. Male hypogonadism is often diagnosed in male patients treated with this drug. This research aims to consider possible side effects induced by MTT in the testis and a hypothetical detrimental effect deriving from androgenic deficiency. Furthermore, considering the increased potentiality of treatment for adrenocortical carcinoma, we want to provide male patients of childbearing age, as in other oncological diseases, the opportunity to consider a sperm cryopreservation program.File | Dimensione | Formato | |
---|---|---|---|
Innocenti_Effect_2023.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
4.83 MB
Formato
Adobe PDF
|
4.83 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.